ECSP056253A - Composicion farmaceutica que contiene un inhibidor de histona desacetilasa - Google Patents

Composicion farmaceutica que contiene un inhibidor de histona desacetilasa

Info

Publication number
ECSP056253A
ECSP056253A EC2005006253A ECSP056253A ECSP056253A EC SP056253 A ECSP056253 A EC SP056253A EC 2005006253 A EC2005006253 A EC 2005006253A EC SP056253 A ECSP056253 A EC SP056253A EC SP056253 A ECSP056253 A EC SP056253A
Authority
EC
Ecuador
Prior art keywords
inhibitor
pharmaceutical composition
composition containing
histone
deacetilase
Prior art date
Application number
EC2005006253A
Other languages
English (en)
Inventor
Osamu Nakanishi
Tatsuo Sugawara
Hideyuki Migita
Yasuhiro Matsuba
Original Assignee
Schering Akti Engesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Akti Engesellschaft filed Critical Schering Akti Engesellschaft
Publication of ECSP056253A publication Critical patent/ECSP056253A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un fármaco anticáncer que tiene un efecto sinérgico debido a la utilización combinada de un derivado de histona desacetilasa tal como la N-(2-aminofenil)-4-[N-(piridín-3-ilmetoxicarbonil)aminometil] benzamida (MS-275) y otra sustancia anticáncer activa.
EC2005006253A 2003-05-26 2005-12-26 Composicion farmaceutica que contiene un inhibidor de histona desacetilasa ECSP056253A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003148073 2003-05-26

Publications (1)

Publication Number Publication Date
ECSP056253A true ECSP056253A (es) 2006-10-25

Family

ID=33475383

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006253A ECSP056253A (es) 2003-05-26 2005-12-26 Composicion farmaceutica que contiene un inhibidor de histona desacetilasa

Country Status (27)

Country Link
US (1) US20070098816A1 (es)
EP (1) EP1626719A1 (es)
JP (1) JP2006526031A (es)
KR (1) KR100938712B1 (es)
CN (2) CN101322707A (es)
AR (1) AR045318A1 (es)
AU (1) AU2004241873C1 (es)
BR (1) BRPI0410959A (es)
CA (4) CA2634709A1 (es)
CL (1) CL2004001278A1 (es)
CO (1) CO5660262A2 (es)
CR (1) CR8163A (es)
CU (1) CU23490B7 (es)
EC (1) ECSP056253A (es)
IL (1) IL171941A0 (es)
ME (1) MEP32308A (es)
MX (1) MXPA05012345A (es)
NO (1) NO20055417L (es)
NZ (1) NZ543591A (es)
PE (1) PE20050206A1 (es)
RS (1) RS20050884A (es)
RU (1) RU2322971C2 (es)
TW (1) TW200505424A (es)
UA (1) UA81499C2 (es)
UY (1) UY28330A1 (es)
WO (1) WO2004103369A1 (es)
ZA (1) ZA200509515B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2006520796A (ja) 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
EP2263694B1 (en) 2003-09-25 2013-06-12 Astellas Pharma Inc. Antitumor agent comprising the histone deacetylase inhibitor FK228 and the topoisomerase II inhibitor doxorubicin
US7446126B2 (en) * 2004-10-08 2008-11-04 Indena S.P.A. Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
EP1712552A1 (en) * 2005-04-11 2006-10-18 INDENA S.p.A. Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel
WO2006066133A2 (en) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2006223086A1 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
US8999289B2 (en) 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR20080032188A (ko) 2005-07-14 2008-04-14 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
US8222423B2 (en) 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
CN103739515B (zh) 2006-02-14 2015-11-25 哈佛大学的校长及成员们 组蛋白去乙酰化酶抑制剂
CA2654540C (en) 2006-05-03 2017-01-17 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
CA2674084C (en) * 2006-12-26 2013-05-14 Pharmacyclics, Inc. Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
WO2009079375A1 (en) * 2007-12-14 2009-06-25 Georgetown University Histone deacetylase inhibitors
CA2731730C (en) 2008-07-23 2017-06-13 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
PE20141062A1 (es) * 2008-08-29 2014-09-19 Bayer Ip Gmbh Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
ES2921576T3 (es) 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
US20120034302A1 (en) * 2009-02-11 2012-02-09 Liangping Yu Particulate composition and the method of making the same
JP2012525371A (ja) * 2009-05-01 2012-10-22 オンコザイム・ファーマ・インコーポレイテッド 癌を治療するためのペンタミジンの組み合わせ
WO2010144371A1 (en) * 2009-06-08 2010-12-16 Gilead Colorado, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
CN102573832B (zh) * 2009-08-25 2015-07-22 阿布拉科斯生物科学有限公司 利用紫杉烷和刺猬抑制剂的纳米颗粒组合物的联合治疗
EP2569313A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
RU2609833C2 (ru) 2011-09-13 2017-02-06 Фармасайкликс Элэлси Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
EP3878851A1 (en) 2011-09-30 2021-09-15 Vertex Pharmaceuticals Incorporated Process for making compounds useful as inhibitors of atr kinase
RU2018108589A (ru) 2011-09-30 2019-02-25 Вертекс Фармасьютикалз Инкорпорейтед Лечение рака поджелудочной железы и немелкоклеточного рака легкого ингибиторами atr
WO2013085902A1 (en) * 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
PT2833973T (pt) 2012-04-05 2017-12-21 Vertex Pharma Compostos úteis como inibidores da cinase atr e terapias de combinação dos mesmos
WO2014055756A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
EP2968282B1 (en) 2013-03-12 2018-05-09 Celgene Quanticel Research, Inc. Histone dementhylase inhibitors
WO2014141129A2 (en) * 2013-03-14 2014-09-18 Grueneberg Dorre A Novel methods, compounds, and compositions for inhibition of ros
WO2015127227A1 (en) * 2014-02-21 2015-08-27 Cleveland Biolabs, Inc. Uses of flagellin for improved chemotherapy
ES2751464T3 (es) 2014-09-17 2020-03-31 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa
EP3355926B1 (en) 2015-09-30 2025-12-24 Vertex Pharmaceuticals Inc. Combination of dna damaging agents and atr inhibitors for use in a method for treating cancer using
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics
WO2025041160A1 (en) * 2023-08-19 2025-02-27 Birla Institute Of Technology And Science (Bits), Pilani Bifunctional conjugate molecules for cancer treatment and process of making the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
OA11659A (en) * 1998-09-25 2004-12-08 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin.
AU4144400A (en) * 1999-04-27 2000-11-10 Mitsubishi Pharma Corporation Preventives/remedies for liver diseases
JP2003513912A (ja) * 1999-11-10 2003-04-15 ワーナー−ランバート・カンパニー 組合せ化学療法
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
JP2003137866A (ja) * 2001-11-01 2003-05-14 Sankyo Co Ltd フェニレンジアミン誘導体

Also Published As

Publication number Publication date
CN101322707A (zh) 2008-12-17
CR8163A (es) 2006-07-14
CN1794991A (zh) 2006-06-28
US20070098816A1 (en) 2007-05-03
CA2634709A1 (en) 2004-12-02
CA2634765A1 (en) 2004-12-02
RS20050884A (sr) 2008-04-04
RU2005140570A (ru) 2006-06-10
CL2004001278A1 (es) 2005-05-06
WO2004103369A1 (en) 2004-12-02
UA81499C2 (en) 2008-01-10
CA2527191A1 (en) 2004-12-02
RU2322971C2 (ru) 2008-04-27
KR20060009371A (ko) 2006-01-31
AR045318A1 (es) 2005-10-26
BRPI0410959A (pt) 2006-07-04
PE20050206A1 (es) 2005-03-26
AU2004241873A1 (en) 2004-12-02
AU2004241873C1 (en) 2009-01-22
MEP32308A (en) 2010-10-10
NO20055417D0 (no) 2005-11-16
NO20055417L (no) 2005-12-19
TW200505424A (en) 2005-02-16
AU2004241873B2 (en) 2008-05-08
CO5660262A2 (es) 2006-07-31
MXPA05012345A (es) 2006-02-08
UY28330A1 (es) 2004-12-31
IL171941A0 (en) 2006-04-10
ZA200509515B (en) 2006-07-26
CA2634766A1 (en) 2004-12-02
EP1626719A1 (en) 2006-02-22
NZ543591A (en) 2009-09-25
KR100938712B1 (ko) 2010-01-25
JP2006526031A (ja) 2006-11-16
CU23490B7 (es) 2010-02-23
AU2004241873B8 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
ECSP056253A (es) Composicion farmaceutica que contiene un inhibidor de histona desacetilasa
BRPI0410727A (pt) composto, composição farmacêutica, e, uso de um composto
NO20055216L (no) Nye hydroksamater som terapeutiske midler
NO20044744L (no) Karbaminsyreforbindelser omfattende et piperazinledd som HDASinbibitorer
EA200970081A1 (ru) Соединения, обладающие потенциирующим действием в отношении активности этионамида, и их применения
BR0308081A (pt) Inibidores de histona desacetilase
BRPI0414581A (pt) derivados de benzimidazol: preparação e aplicações farmacêuticas
TW200510375A (en) New compounds
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
EA200700138A1 (ru) Замещённые индолильные алкиламинопроизводные в качестве новых ингибиторов гистондеацетилазы
EA200801243A1 (ru) Фармацевтическое применение замещенных амидов
HN2003000044A (es) Esteres hidroxamato del acido n - (4-fenil sustituido)-antranilico.
EA200702568A1 (ru) Гетеробициклические ингибиторы металлопротеазы и их применение
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
CL2003002611A1 (es) Compuestos derivados del acido tiofeno hidroxamico, 2-hidroxamida-5-[(aril o heteroaril)-disutituido-metil]-amida del acido tiofeno-2,5-dicarboxilico enantiomeros, composicion farmaceutica, procedimiento de preparacion, y su uso para el tratamiento d
EA200300334A1 (ru) Новая соль периндоприла и содержащие ее фармацевтические композиции
UY27618A1 (es) Ésteres hidroxamato de ácido n-(4-fenil-sustituido)-antranílico
BRPI0615690B8 (pt) compostos heterocíclicos de hidroxamato, seus usos e composição farmacêutica
CL2008000683A1 (es) Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de la enzima de conversion de angiotensina (ace); formulacion de dosis unitaria; y uso en el tratamiento de la diabetes.
GB2427405A (en) Novel hydroxamates as therapeutic agents
CL2009001150A1 (es) Compuestos derivados de n-(2-amino-fenil)-acrilamidas, inhibidor de la histona-desacetilasa (hdac); procedimiento de preparacion; composicion faramceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
MXPA02010828A (es) Composicion farmaceutica en capsulas que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor.
AR055107A1 (es) Furoato de n-{2-[((2s)-3-{[1-(4-clorobencil)piperidin-4-il]amino}-2-hidroxi-2-metilpropil)oxi]-4-hidroxifenil} acetamida,composiciones farmaceuticas que los contienen y usos para tratar afecciones o enfermedades donde actuan como moduladores del receptor de quimioquina 1(ccr1)
MX2008008470A (es) Nuevos derivados pirrolicos con actividad inhibidora de desacetilasa de histonas.
EA200700067A1 (ru) Фармацевтическая композиция, содержащая производные пиперазина